Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

被引：1
|
作者：
Pemmaraju, Naveen
Carter, Bing Z.
Kantarjian, Hagop M.
Cortes, Jorge E.
Kadia, Tapan M.
Garcia-Manero, Guillermo
DiNardo, Courtney D.
Bose, Prithviraj
Pierce, Sherry
Zhou, Lingsha
Estrov, Zeev
Tuttle, Carla Kay
Salinas, Karina
Mak, Po Yee
Verstovsek, Srdan
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3105.3105
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3105
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Sliwa, Thamer
    Beham-Schmid, Christine
    Burgstaller, Sonja
    Buxhofer-Ausch, Veronika
    Gastl, Guenther
    Geissler, Klaus
    Krauth, Maria
    Krippl, Peter
    Lang, Alois
    Petzer, Andreas
    Woehrer, Stefan
    Woelfler, Albert
    Gisslinger, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (9-10) : 293 - 302
  • [22] Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post - Polycythemia, Vera Myelofibrosis (PPV - MF), and Post Essential Thrombocythemia Myelofibrosis (PET - MF)
    Vargas, Pablo
    Ovilla, Roberto
    Alvarado, Martha
    Lopez, Manuel
    Hurtado Monroy, Rafael
    Carlos Solis, Juan
    Limon, Alejandro
    Agreda, Gladys
    Silva, Salvador
    Julio Kassack, Juan
    Zavala, Saida
    Aguilar, Carlos
    Baez, Enrique
    Barrera, Esperanza
    Osuna, Antonio
    Morales, Javier
    Herrera, Aquileo
    BLOOD, 2012, 120 (21)
  • [23] THE SELECTIVE JANUS KINASE (JAK) INHIBITOR, INCB018424, SHOWS EFFICACY IN A PHASE I/II TRIAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H.
    Pardanani, A.
    Thomas, D.
    Cortes, J.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Fridman, J.
    Tefferi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 179 - 179
  • [24] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Thamer Sliwa
    Christine Beham-Schmid
    Sonja Burgstaller
    Veronika Buxhofer-Ausch
    Günther Gastl
    Klaus Geissler
    Maria Krauth
    Peter Krippl
    Alois Lang
    Andreas Petzer
    Stefan Wöhrer
    Albert Wölfler
    Heinz Gisslinger
    Wiener klinische Wochenschrift, 2017, 129 : 293 - 302
  • [25] Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
    Chen, Xuejun
    Williams, William V.
    Sandor, Victor
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (07): : 721 - 730
  • [26] Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis
    Passamonti, Francesco
    Mora, Barbara
    Barraco, Daniela
    Maffioli, Margherita
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (03) : 173 - 182
  • [27] Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis
    Francesco Passamonti
    Barbara Mora
    Daniela Barraco
    Margherita Maffioli
    Current Hematologic Malignancy Reports, 2018, 13 : 173 - 182
  • [28] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
    A Tefferi
    L Saeed
    C A Hanson
    R P Ketterling
    A Pardanani
    N Gangat
    Leukemia, 2017, 31 : 2851 - 2852
  • [29] Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval
    Pemmaraju, Naveen
    Newberry, Kate J.
    Manshouri, Taghi
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA RESEARCH, 2017, 59 : 110 - 116
  • [30] Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan
    Hou, Hsin-An
    Lin, Chien-Chin
    Kuo, Ming-Chung
    Lin, Shyuann-Yuh
    Gau, Jyh-Pyng
    Wang, Ming-Chung
    Chang, Ming-Chih
    Chen, Tsung-Chih
    Yeh, Su-Peng
    Chen, Yeu-Chin
    Huang, Cih-En
    Chen, Chieh-Wen
    Lee, Yee-Ming
    Ku, Fan-Chen
    Shih, Lee-Yung
    BLOOD, 2019, 134
12345